Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118881344 | 11888134 | 4 | F | 20160815 | 20160105 | 20160822 | EXP | US-ASTRAZENECA-2015SF30665 | ASTRAZENECA | 58.00 | YR | M | Y | 0.00000 | 20160822 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118881344 | 11888134 | 1 | PS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | 22047 | 300 | MG | PROLONGED-RELEASE TABLET | QD | |||||||
| 118881344 | 11888134 | 2 | C | OTHER MEDICATIONS | UNSPECIFIED INGREDIENT | 1 | 0 |
Indications of drugs used
| no results found |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 118881344 | 11888134 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 118881344 | 11888134 | Depressed mood | |
| 118881344 | 11888134 | Gastric dilatation | |
| 118881344 | 11888134 | Gout | |
| 118881344 | 11888134 | Hypophagia | |
| 118881344 | 11888134 | Increased appetite | |
| 118881344 | 11888134 | Mental disorder | |
| 118881344 | 11888134 | Metabolic disorder | |
| 118881344 | 11888134 | Renal disorder | |
| 118881344 | 11888134 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |